$5M Partnership Targets Alpha-Synuclein Biomarkers for Alzheimer's and Parkinson's
Event summary
- $5 million partnership between ADDF's Diagnostics Accelerator and The Michael J. Fox Foundation to develop minimally invasive biomarkers for Alzheimer's and Parkinson's.
- Focus on detecting alpha-synuclein, a protein clumping in brains of nearly all 6 million people with Parkinson's and 30-50% of those with Alzheimer's.
- Builds on prior investments including an assay in cerebrospinal fluid (CSF) for early detection of alpha-synuclein pathology.
- Aims to advance scalable, minimally invasive biomarker approaches consistent with DxA's mission.
The big picture
The partnership underscores a strategic shift toward precision medicine in neurodegenerative diseases, leveraging venture philanthropy to address high-impact challenges. By focusing on co-pathologies like alpha-synuclein, the collaboration aims to bridge gaps in diagnostics, ultimately enabling more targeted treatments and personalized care. The $5 million investment reflects growing industry momentum toward scalable, minimally invasive biomarkers that can keep pace with the complexity of disease biology.
What we're watching
- Biomarker Validation
- The pace at which the partnership can validate and scale minimally invasive biomarkers for alpha-synuclein.
- Cross-Disease Insights
- Whether combining Parkinson's and Alzheimer's research will uncover common mechanisms accelerating biomarker discovery.
- Clinical Trial Impact
- How improved diagnostics will affect the enrollment of right participants in clinical trials and evaluation of therapies.
Related topics